Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Generic Programmatic and Clinical Guide for the Introduction of New Drugs and Shorter Regimen for Treatment of Multi/Extensively Drug-Resistant Tuberculosis

Guideline
Generic Programmatic and Clinical Guide for the Introduction of New Drugs and Shorter Regimen for Treatment of Multi/Extensively Drug-Resistant Tuberculosis

This document describes the steps necessary to implement the shorter regimen and the new drugs for drug-resistant TB treatment, including diagnosis and bacterial confirmation of drug resistance, treatment regimen design, monitoring of treatment efficacy and safety, and programmatic evaluation.

Author:

US Agency for International Development, KNCV Tuberculosis Foundation, KNCV Tuberculosis Foundation, Bureau for Global Health, Office of Health Infectious Diseases and Nutrition, USAID, KNCV

Audiences:

Health Professionals, International Agencies

Topic:

MDR TB, TB Treatment, Extensively Drug-Resistant TB (XCR TB)

View Webpage

Related Materials

Generic Programmatic and Clinical Guide for the Introduction of new drugs and Shorter Regimens for the Treatment of Multi/Extensively Drug-Resistant Tuberculosis

This document describes the steps necessary to implement the shorter regimen and the new drugs for drug-resistant TB treatment, including diagnosis and bacterial confirmation of drug resistance, treatment regimen design, monitoring of treatment efficacy and safety, and programmatic evaluation.

Guidance on Requirements for QTc Measurement in ECG Monitoring When Introducing New Drugs and Shorter Regimens for the Treatment of Drug-Resistant Tuberculosis

This document describes the steps necessary to measure the corrected QT (QTc) interval from electrocardiography (ECG) monitoring for patients being treated either with the shorter treatment regimen or the new drugs for drug-resistant TB treatment.

Tool

Multi-Drug Resistant Tuberculosis

This video summarizes the key elements of the multi-faceted, private-public partnership that has been assembled by Lilly to meet the challenge of MDR-TB. Several world-recognized experts from academia, international agencies, and from within the company talk about the challenges that developing nations face in implementing sound containment programs given the lack of awareness, adequately trained personnel and access to affordable drugs.

Webpage

Global resources for the prevention,
management, and elimination of TB.